ASCO 2022 Conference Coverage
ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial
By
ASCO 2022 Conference Coverage
FEATURING
Stéphane De Botton
By
ASCO 2022 Conference Coverage
FEATURING
Stéphane De Botton
Login to view comments.
Click here to Login
Leukemia